EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 / No 10 (Octobre 2016) Med Sci (Paris), 32 10 (2016) 861-866 References
Free Access
Issue
Med Sci (Paris)
Volume 32, Number 10, Octobre 2016
Page(s) 861 - 866
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163210019
Published online 19 October 2016
  1. Lewington S, Clarke R, Qizilbash N, et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 ; 360 : 1903–1913. [CrossRef] [PubMed] [Google Scholar]
  2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009 ; 338 : b1665. [CrossRef] [PubMed] [Google Scholar]
  3. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987 ; 1 : 581–584. [CrossRef] [PubMed] [Google Scholar]
  4. Chalmers J. Is a blood pressure target of < 130/80 mmHg still appropriate for high-risk patients? Circulation 2011 ; 124 : 1700–1702. [CrossRef] [PubMed] [Google Scholar]
  5. Cooper-DeHoff RM, Handberg EM, Mancia G, et al. INVEST revisited: review of findings from the international verapamil SR-trandolapril study. Expert Rev Cardiovasc Ther 2009 ; 7 : 1329–1340. [CrossRef] [PubMed] [Google Scholar]
  6. Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press 2015 ; 1–10. [CrossRef] [PubMed] [Google Scholar]
  7. Turnbull F, Neal B, Algert C, et al. Blood pressure lowering treatment trialists’ collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 ; 165 : 1410–1419. [CrossRef] [PubMed] [Google Scholar]
  8. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1575–1585. [CrossRef] [PubMed] [Google Scholar]
  9. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation 2010 ; 122 : 847–849. [CrossRef] [PubMed] [Google Scholar]
  10. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013 ; 382 : 507–515. [CrossRef] [PubMed] [Google Scholar]
  11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 ; 358 : 1033–1041. [CrossRef] [PubMed] [Google Scholar]
  12. Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med 2012 ; 9 : e1001293. [CrossRef] [PubMed] [Google Scholar]
  13. 2013 ESH-ESC guidelines for the management of arterial hypertension. J Hypertens 2013 ; 31 : 1281–1357. [CrossRef] [PubMed] [Google Scholar]
  14. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015 ; 373 : 2103–2116. [CrossRef] [PubMed] [Google Scholar]
  15. MacMahon S, Neal B, Rodgers A. Hypertension: time to move on. Lancet 2005 ; 365 : 1108–1109. [CrossRef] [PubMed] [Google Scholar]
  16. Chobanian AV. Time to reassess blood-pressure goals. N Engl J Med 2015 ; 373 : 2093–2095. [CrossRef] [PubMed] [Google Scholar]
  17. Drazen JM, Morrissey S, Campion EW, et al. A SPRINT to the finish. N Engl J Med 2015 ; 373 : 2174–2175. [CrossRef] [PubMed] [Google Scholar]
  18. Perkovic V, Rodgers A. Redefining blood-pressure targets–SPRINT starts the marathon. N Engl J Med 2015 ; 373 : 2175–2178. [CrossRef] [PubMed] [Google Scholar]
  19. Jones DW, Weatherly L, Hall JE. SPRINT: What remains unanswered and where do we go from here? Hypertension 2016 ; 67 : 261–262. [PubMed] [Google Scholar]
  20. Cushman WC, Whelton PK, Fine LJ, et al. SPRINT Trial results: Latest news in hypertension management. Hypertension 2016 ; 67 : 263–265. [PubMed] [Google Scholar]
  21. Esler M. SPRINT, or false start, toward a lower universal treated blood pressure target in hypertension. Hypertension 2016 ; 67 : 266–267. [PubMed] [Google Scholar]
  22. Touyz RM, Dominiczak AF. Successes of SPRINT, but still some hurdles to cross. Hypertension 2016 ; 67 : 268–269. [CrossRef] [PubMed] [Google Scholar]
  23. Kjeldsen SE, Oparil S, Narkiewicz K, et al. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press 2016 ; 25 : 1–3. [CrossRef] [PubMed] [Google Scholar]
  24. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 ; 311 : 507–520. [Google Scholar]
  25. Yusuf S, Sleight P, Pogue J, et al. The heart outcomes prevention evaluation (HOPE) study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 ; 342 : 145–153. [CrossRef] [PubMed] [Google Scholar]
  26. Brugts JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009 ; 30 : 1385–1394. [CrossRef] [PubMed] [Google Scholar]
  27. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial: lipid lowering arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003 ; 361 : 1149–1158. [CrossRef] [PubMed] [Google Scholar]
  28. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. Stroke prevention by aggressive reduction in cholesterol levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 ; 355 : 549–559. [CrossRef] [PubMed] [Google Scholar]
  29. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 ; 351 : 1755–1762. [Google Scholar]
  30. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010 ; 303 : 1180–1187. [CrossRef] [PubMed] [Google Scholar]
  31. Bress AP, Tanner RM, Hess R, et al. Generalizability of SPRINT results to the U.S. adult population. J Am Coll Cardiol 2016 ; 67 : 463–472. [CrossRef] [PubMed] [Google Scholar]
  32. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999 ; 341 : 709–717. [CrossRef] [PubMed] [Google Scholar]
  33. Collins R, Peto R, MacMahon SW, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Lancet 1990 ; 335 : 827–838. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.